Drug-induced Valvulopathy: An Update

Toxicologic Pathology - Tập 38 Số 6 - Trang 837-848 - 2010
Chandikumar S. Elangbam1
1Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, USA

Tóm tắt

Drug-induced valvulopathy is a serious liability for certain compound classes in development and for some marketed drugs intended for human use. Reports of valvulopathy led to the withdrawal of fenfluramines (anorexigens) and pergolide (antiparkinson drug) from the United States market in 1997 and 2007, respectively. The mechanism responsible for the pathogenesis of valvulopathy by these drugs is likely a result of an “off-target” effect via activation of 5-hydroxytryptamine (5-HT) 2B receptor (5-HT2BR) expressed on heart valve leaflets. Microscopically, the affected valve leaflets showed plaques of proliferative myofibroblasts in an abundant extracellular matrix, composed primarily of glycosaminoglycans. However, the valvular effects caused by fenfluramines and pergolide were not initially predicted from routine preclinical toxicity studies, and to date there are no specific validated animal models or preclinical/toxicologic screens to accurately predict drug-induced valvulopathy. This review covers the structure and function of heart valves and highlights major advances toward understanding the 5-HT2BR-mediated pathogenesis of the lesion and subsequently, development of appropriate animal models using novel techniques/experiments, use of functional screens against 5-HT2BR, and more consistent sampling and pathologic evaluation of valves in preclinical studies that will aid in avoidance of future drug-induced valvulopathy in humans.

Từ khóa


Tài liệu tham khảo

10.1161/CIRCULATIONAHA.105.591768

10.1016/S1474-4422(07)70218-1

10.1016/j.tvjl.2008.09.010

10.1016/j.jcpa.2009.02.002

10.1016/j.tvjl.2007.11.011

10.1016/0002-8703(74)90251-8

10.1212/01.WNL.0000129842.49926.07

10.1212/01.wnl.0000225186.76323.69

10.1001/jama.1997.03550210025016

10.1016/S0014-2999(99)00100-4

10.1161/01.ATV.0000196624.70507.0d

10.1056/NEJM199707033370107

10.2353/ajpath.2009.080750

10.1056/NEJM199708283370901

10.2353/ajpath.2009.081101

10.1016/j.matbio.2005.06.007

10.1186/1741-7015-6-34

10.1111/j.1067-1927.2005.130102.x

10.1177/0192623307312707

10.1016/j.amjcard.2007.06.045

10.1093/eurheartj/ehm263

10.1152/ajpheart.01177.2008

10.1016/j.etp.2008.03.005

10.1369/jhc.4A6500.2005

10.1016/j.etp.2006.08.001

European Medicines Agency (EMEA). (2008). Questions and answers on the review of ergot-derived dopamine agonists. EMEA http://www.emea.europa.eu/pdfs/general/direct/pr/31905408en.pdf

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2005). Annual Report 2005: The State of the Drugs Problem in Europe. EMCDDA http://annualreport.emcdda.eu.int

Fanburg B. L., 1997, Am J Physiol, 272, L795

10.1016/j.carpath.2007.02.008

10.1161/01.CIR.99.1.156

Fitzgerald L. W., 2000, Mol Pharmacol, 57, 75

10.1016/j.bbadis.2008.01.006

10.1097/00000441-196707000-00001

10.1093/glycob/cwh076

Greaves P. (2007). Cardiovascular system. In Histopathology of Preclinical Toxicity Studies – interpretation and relevance in drug safety evaluation (Greaves P. ed.), pp. 270–333. Elsevier, New York.

10.1016/j.athoracsur.2006.11.031

10.1016/j.carpath.2008.05.001

10.1161/01.CIR.0000159356.42064.48

Hauck A. J., 1990, Arch Pathol Lab Med, 114, 62

10.1038/37284

Hendrikx M., 1996, J Heart Valve Dis, 5, 235

10.1001/jama.283.13.1738

10.2353/ajpath.2007.070112

10.1124/mol.109.058057

10.1016/S0021-9258(17)35666-1

10.1016/j.ejphar.2005.03.010

10.1016/S0002-9440(10)64489-6

10.1056/NEJM199809103391102

10.1161/01.CIR.101.17.2071

10.1160/TH04-08-0522

Keane J. F., 1993, Circulation, 87, 16

10.1615/CritRevEukaryotGeneExpr.v14.i3.40

10.1002/jcp.10030

10.1016/S0008-6363(00)00003-1

10.2353/ajpath.2008.080365

10.2353/ajpath.2007.070251

10.1016/S0006-2952(98)00059-8

10.1016/j.carpath.2008.08.001

10.1161/01.CIR.94.3.368

10.1037/1064-1297.13.3.244

10.1101/gad.1350705

Maxie M. G., 2007, Jubb, Kennedy and Palmer’s Pathology of Domestic Animals, 1

10.1016/S1054-8807(02)00110-2

10.1161/CIRCULATIONAHA.105.554667

10.1006/jsre.1994.1102

10.1124/jpet.102.039867

10.1136/bmj.2.5915.365

Mulholland D. L., 1996, Can J Cardiol, 12, 231

10.1016/S1054-8807(96)00115-9

National Toxicology Program (NTP) (1991). NTP Technical Report on the Toxicology and Carcinogenesis Studies of dl-Amphetamine Sulfate (CAS No. 60-13-9) in F344/N Rats and B6C3F1 Mice (Feed Studies). NTP TR-387, NIEHS, Research Triangle Park, NC (http://ntp-server.niehs.nih.gov/index).

10.1021/cr078224o

10.1016/j.ydbio.2008.01.003

Pena-Silva R. A., 2009, Am J Physiol, 297, H1354

Plendl J., 2006, Dellmann’s Textbook of Veterinary Histology, 117

10.4065/77.12.1280

10.1161/hc4601.099489

Rajamannan N. M., 2001, J Heart Valve Dis, 10, 827

10.7326/0003-4819-117-1-50

10.1023/A:1025383913444

10.1056/NEJMp068265

10.1097/MJT.0b013e31817fde95

10.1161/01.CIR.102.23.2836

Roy A., 2000, J Heart Valve Dis, 9, 459

10.1067/mhj.2002.126733

10.1056/NEJMoa062222

10.1016/j.carpath.2005.03.005

Schoen F. J., 2005, Robbins and Cotran Pathologic Basis of Disease, 555

10.1016/j.carpath.2006.05.001

Schoen F. J., 2001, Cadiovascular Pathology, 402

10.1097/00045415-200211000-00005

10.1517/17425255.1.3.377

10.1124/mol.63.6.1223

10.1161/01.RES.0000161998.92009.64

10.1161/01.CIR.100.25.e133

10.1016/S1054-8807(99)00019-8

10.1007/s00702-008-0179-4

Taylor P. M., 2000, J Heart Valve Dis, 9, 150

10.1161/CIRCULATIONAHA.105.171600

10.1016/S0140-6736(04)15945-X

10.1016/B978-012330215-1/50036-3

10.1161/01.RES.0000207384.81818.d4

10.1161/01.RES.0000070112.80711.3D

10.5858/2001-125-1555-AAMFPV

10.1161/01.RES.0000136520.07995.aa

Waltenberger J., 1993, Am J Pathol, 142, 71

10.1016/S0955-0674(02)00375-7

10.1007/978-1-4615-3770-0_3

10.1056/NEJMra012586

10.1056/NEJMoa054830